Articles tagged with Fatty Liver Disease
A new approach to treating non-alcoholic fatty liver disease (NAFLD) has been discovered, utilizing resistant starch to reduce fat accumulation and inflammation in the liver. The study found that consuming resistant starch daily led to an increase in beneficial gut bacteria, which positively impacted liver health.
A new analysis of liver cancer identified racial and ethnic differences in cause, as well as emerging trends for this highly fatal disease. The study found that liver cancer disproportionately affects people of low socioeconomic status, immigrants, veterans, and incarcerated populations.
A new gene therapy study has identified microRNA-22 as a potential treatment for liver cancer, achieving better survival outcomes and reducing inflammation compared to the current FDA-approved drug lenvatinib. The treatment was administered via a single intravenous injection and showed no observable toxicity.
A new study led by Wayne State University aims to discover gene-heavy metal interactions in human livers that contribute to nonalcoholic fatty liver disease (NAFLD). The research, funded by the National Institute of Environmental Health Sciences, will investigate how naturally accumulated metals interact with the liver genome.
Recent meta-analysis finds MAFLD associated with higher risk of chronic kidney disease (CKD) in adults. People with MAFLD are 20% more likely to develop CKD than those without the condition.
Scientists have discovered a potential new treatment approach for non-alcoholic fatty liver disease by targeting a receptor called Adgrf1. Overexpressing Adgrf1 improved insulin sensitivity and reduced lipid accumulation in liver cells, suggesting its role in fat metabolism.
Yale researchers have created a functional humanized liver in living mice, enabling scientists to study human-specific mechanisms for regulating cholesterol levels and treating chronic liver diseases. The discovery uses progenitor stem cells and mature cells from a human liver to mimic the cellular functions of a healthy human liver.
Researchers at CU Anschutz Medical Campus identify fructose as a central conduit to obesity and diseases. Fructose works differently than other nutrients by lowering active energy, stimulating food intake and leading to weight gain.
A study published in Hepatology reveals that abnormal pre-mRNA splicing is associated with liver disease caused by excessive alcohol consumption. The researchers propose targeting specific splicing factors as a novel approach to mitigate the disease.
Research at Duke-NUS Medical School suggests that a specific mechanism involving the omega-3 transporter protein Mfsd2a prevents the liver from storing excess fat, which could lead to non-alcoholic fatty liver disease. Dietary supplements containing this lipid may help prevent the condition.
A large-scale study shows that repeated liver stiffness measurements can predict patient outcomes in chronic liver disease. The researchers found that monitoring changes in liver stiffness over time provides a more accurate assessment of patient risk than single measurements.
Researchers have identified a potential new drug that improves both liver fibrosis and inflammation in patients with nonalcoholic steatohepatitis (NASH). The drug, Pegozafermin, mimics the body's natural hormone FGF21, controlling energy use and lipid metabolism in the liver.
A new research centre will focus on developing new types of RNA medicine for treating metabolic diseases. The centre, led by Professor Jørgen Kjems at Aarhus University, aims to create targeted treatments for conditions like diabetes and atherosclerosis.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
Researchers found that B cells in the gastrointestinal tract play a crucial role in promoting liver cancer by activating autoaggressive T cells and producing IgA antibodies. When B cells are turned off, inflammation and fibrosis regress in mice, suggesting new ways to prevent NASH and liver cancer.
A new substudy of the STEP TEENS trial shows that semaglutide significantly reduces levels of liver enzymes, including alanine aminotransferase (ALT), which are indicators of liver damage. The study found improvements in ALT levels with weight loss of ≥10%.
Researchers found that fatty liver cells secrete proteins and genetic material that promote the spread of colorectal cancer to the liver. This condition is likely underdiagnosed, affecting over 40% of patients with colorectal cancer, according to a new study published in Cell Metabolism.
A pilot study found that high-dose tadalafil improved metabolic control and reduced hemoglobin A1c levels by 2.50 mmol/mol in patients with well-controlled type 2 diabetes. The treatment also showed increased blood flow, liver values, and metabolism.
Researchers at West Virginia University found that bariatric surgery significantly reduces the risk of major cardiovascular events and death in patients with NAFLD. The study included 9,374 adult patients with NAFLD and obesity, who underwent either Roux-en-Y gastric bypass or sleeve gastrectomy.
A recent study by Osaka Metropolitan University researchers found that the Japanese diet pattern, rich in soy products, seafood, and seaweed, inhibits liver fibrosis progression. High muscle mass, also associated with this diet, shows a lower degree of liver fibrosis progression.
A new study published in The Lancet shows that metabolic surgery is more effective than medications and lifestyle interventions in treating advanced non-alcoholic fatty liver disease. The trial compared three active treatments and found that surgery reversed inflammation and improved liver fibrosis, leading to better overall health ben...
Scientists discover that milk-derived extracellular vesicles can repair damaged gut barriers and prevent bacterial toxins from leaking into the bloodstream. The study shows promising results in treating leaky gut syndrome and related diseases such as inflammatory bowel disease and non-alcoholic fatty liver disease.
A research team led by the University of Cincinnati's Atsuo Sasaki aims to understand how an enzyme regulates lysosomal function based on energy molecule GTP. This study could lead to new treatments for cancer, neurodegenerative diseases and anti-aging.
Researchers have developed a glycine-based tripeptide that successfully treats nonalcoholic fatty liver disease in non-human primates and mice. The compound, DT-109, reverses fat buildup and prevents scarring by stimulating fatty acid degradation and antioxidant formation.
Researchers created the integrated-gut-liver-on-a-chip platform to examine how gut and liver cells interact, particularly in relation to non-alcoholic fatty liver disease. The study showed significant changes in gene expression and DNA damage when free fatty acids were introduced, leading to cell death similar to severe cases of NAFLD.
A study from Indiana University School of Medicine found that people with NAFLD have significantly decreased levels of the liver enzyme CYP2C19, which is important for medication processing. This decrease may lead to slower clearance of certain medications and reduced effectiveness of medicines like antidepressants and clopidogrel.
A recent study found that certain microbial metabolites are associated with liver fat content in individuals with fatty liver disease. The researchers identified degradation products of amino acids and differences in testosterone levels as potential biomarkers.
Researchers developed a small-molecule drug that limits magnesium transport into cellular power plants, resulting in skinny, healthy mice. The findings hold significant implications for preventing cardiometabolic diseases like heart attack and stroke, as well as reducing liver cancer risk.
New research from the University of Missouri establishes a link between western diets high in fat and sugar and non-alcoholic fatty liver disease. The study found that a specific bacteria called Blautia producta and a lipid caused liver inflammation and fibrosis, leading to non-alcoholic steatohepatitis.
Researchers have developed a new imaging approach to diagnose advanced non-alcoholic fatty liver disease (NASH). The enzyme-sensitive nanoprobe emits signals that can be detected by MRI techniques, providing more accurate and sensitive data for diagnosis. This breakthrough aims to improve the treatment outcomes of NASH patients.
Researchers created human organoid models of fatty liver disease to shed light on drug responses and disease biology. The models identified a common mechanism for effective drugs that block lipid generation from sugars, suggesting personalized medicine applications.
A recent study published in JHEP Reports found that individuals with low thigh muscle volume and high muscle fat infiltration had an increased mortality risk. The researchers also discovered that poor muscle health was not associated with a worsened prognosis in people with fatty liver disease.
Researchers found that alternate-day fasting combined with exercise decreased liver fat, weight, and ALT enzymes in patients with nonalcoholic fatty liver disease. The study suggests that this lifestyle modification may be a good option for treating the condition without pharmaceuticals.
A mutant SRSF1 gene may cause severe nonalcoholic fatty liver disease (NASH), researchers have found. Mice lacking the gene develop all three hallmarks of NASH: excess fat, inflammation, and scarring in the liver. The study suggests that DNA damage in liver cells triggers this pathology, highlighting the need to protect the genome.
Scientists have discovered that wrinkles in the cellular nucleus may be involved in common metabolic diseases such as diabetes and fatty liver disease. The new findings suggest that targeting these wrinkles could lead to novel treatments for non-alcoholic fatty liver disease, which affects 40% of people over age 70.
Researchers from DZD and Harvard Medical School identified key hepatokines dysregulated in NAFLD, predicting type 2 diabetes and cardiovascular events. Hepatokine cluster analysis revealed distinct subtypes of people with fatty liver having different pathomechanisms of insulin resistance.
A study identified an antibody candidate that blocks the protein VEGF-B, presenting a possible therapeutic option for fatty liver disease. The treatment method involves keeping fatty acids in adipose tissue to prevent liver accumulation.
A recent study found that consuming soy flour rich in B-conglycinin can reduce LDL cholesterol levels and lower the risk of metabolic diseases. The protein inhibits HMGCR, a liver enzyme involved in triglyceride and low-density lipoprotein metabolism.
A new study by the University of Coimbra found that higher coffee intake is associated with reduced NAFLD severity in overweight people with T2D. Caffeine and polyphenols in coffee may help alleviate liver fibrosis and improve glucose homeostasis.
A recent study found that eating fast food is associated with nonalcoholic fatty liver disease, a potentially life-threatening condition. Researchers discovered that people with obesity or diabetes who consume high amounts of fast food have severely elevated levels of fat in their liver.
Researchers have identified novel candidate drug targets for advanced non-alcoholic fatty liver disease (NAFLD) using innovative methods. A network of cell-to-cell communication driving scarring was uncovered, and one pair of proteins showed promise as a new treatment.
A study published in Journal of Hepatology found that non-alcoholic fatty liver disease (NAFLD) can cause a decrease in oxygen supply to the brain and inflammation to brain tissue. The research identified Monocarboxylate Transporter 1 (MCT1) as a potential therapeutic target for protecting against NAFLD-induced brain dysfunction.
Researchers developed a new epigenetic biomarker, GrimAge version 2, which leverages two DNAm-based estimators of plasma proteins to predict mortality risk. The study found that GrimAge 2 outperforms existing clinical biomarkers in predicting mortality across multiple racial/ethnic groups and associations with age-related conditions.
This study explores the molecular mechanisms of steatosis-to-NASH progression using two mouse models and identifies genes, non-coding RNAs, proteins, and plasma metabolites involved. GDF3 is found to be up-regulated in NASH mice and serves as a potential non-invasive diagnostic biomarker for NASH patients.
A randomized controlled trial found that a low-carbohydrate, high-fat diet helped patients with type 2 diabetes achieve better weight loss and glucose control over a 6-month intervention compared to a high-carb, low-fat diet. However, changes were not sustained 3 months after the intervention.
Researchers found non-heavy alcohol use associated with liver fibrosis and at-risk nonalcoholic steatohepatitis (NASH) in a large cohort of participants. The study highlights the importance of reducing alcohol intake and adherence to US Dietary Guidelines for liver health.
A Cedars-Sinai study found that even subtle forms of liver disease directly impact heart health, with elevated FIB-4 scores associated with abnormalities in heart function and vascular dimension. Cardiac MRI scans revealed that nearly 86% of patients had at least one heart abnormality.
Researchers found that dietary saturated/trans fats, but not cholesterol, can trigger hepatic angiogenesis and lymphangiogenesis in mice, leading to the promotion of hepatic tumors. This process is driven by the JNK-HIF1α-VEGF-C axis.
Researchers found that P2-HNF4α expression is associated with p-STAT3 and c-Myc expression in NAFLD patients, suggesting potential biomarkers for hepatocellular carcinoma (HCC) risk. Additionally, p-STAT3 expression was linked to hypertension, while c-Myc expression was associated with advanced fibrosis.
A new AI-powered blood test, DELFI, has been developed to detect liver cancer with high accuracy. The test detected over 80% of liver cancers in a study of 724 individuals, with an overall sensitivity of 88% and specificity of 98%.
Researchers found that a genetic mutation associated with liver disease confers different levels of risk depending on a patient's diabetic status. In diabetic patients, the mutation predisposes them to nonalcoholic fatty liver disease, but in nondiabetic patients, it protects against liver disease.
A Rutgers study of 86,964 adults with obesity and NAFLD found that bariatric surgery reduced the risk of major cardiovascular events by 49% compared to nonsurgical care. This is significant because heart disease is a leading cause of death in the US, and NAFLD can lead to liver damage and inflammation.
Researchers found that first-degree relatives of patients with advanced fibrosis are at a 15% risk of developing nonalcoholic fatty liver disease. Early screening for advanced fibrosis among siblings and offspring of patients can help prevent the progression to cirrhosis or liver failure.
Scientists at deCODE genetics have discovered rare, protective loss-of-function variants that point to potential drug targets for NAFLD. The study identified biomarkers of disease and disease progression, which can help develop non-invasive diagnostic tools.
A study found that leptin stimulates liver fat export and lowers liver fat content in healthy men, suggesting a new approach for treating fatty liver disease. The findings imply that the brain plays a role in liver fat metabolism via the autonomic nervous system, opening up potential new treatment options.
Researchers found that liver cells cannot undergo necroptosis, a form of cell death previously thought to drive liver diseases. This revelation points to a new therapeutic intervention strategy and resolves crucial unanswered questions in the field.
Researchers found that hepatocyte adenosine kinase promotes excessive fat deposition and liver inflammation, suggesting a key role in the pathogenesis of nonalcoholic fatty liver disease. Dietary changes may help prevent or reduce NAFLD severity by inhibiting ADK activity.
A preclinical study suggests that spermidine can help alleviate the pathological features of NASH, a condition associated with cardiac and kidney disease. The compound improves mitochondrial function, reduces inflammation, and prevents scar tissue formation.
A new Chinese Medical Journal review article elucidates the potential contributors to non-alcoholic fatty liver disease (NAFLD) progression, highlighting the role of bile acid and sphingolipid biology. Researchers summarize current understanding of NAFLD, its progression, and potential therapeutic strategies.
A lab study found that high cholesterol intake worsens fatty liver disease progression by driving inflammation and scarring. The researchers also discovered long-lasting dysfunction in immune cells responsible for fighting liver damage. Moderation is key to maintaining a healthy diet, according to the study's findings.